A randomized controlled trial for gualou danshen granules in the treatment of unstable angina pectoris patients with phlegm-blood stasis syndrome.

Abstract

INTRODUCTION:

Unstable angina pectoris is an acute exacerbation secondary to coronary artery occlusion. In routine clinical treatment, patients with unstable angina pectoris are prone to recurrence or aggravation of symptoms. Based on the traditional Chinese medicine (TCM) theory, phlegm, and blood stasis are one of the main pathological factors of unstable angina pectoris. The treatment of unstable angina pectoris with phlegm-blood stasis syndrome by Gualou Danshen granules (GLDS) has been the focus of many clinical trials. However, there is no evidence to prove the safety or clinical efficacy of GLDS.

METHODS AND ANALYSIS:

In this study, we will conduct a 4-week randomized, controlled feasibility study, with participants recruited from Guang'anmen Hospital, Chinese Academy of Traditional Chinese Medicine. Sixty subjects are to be diagnosed as having phlegm-blood stasis syndrome and randomly divided into a treatment group (GLDS) and placebo group in a 1:1 ratio. Result measurements will include therapeutic indicators (Clinical Symptom Rating Scale, Phlegm-Blood Stasis Syndrome Scale, and Seattle Angina Questionnaire) and safety indicators (blood routine, urine routine, electrocardiogram, liver function, and kidney function). The clinical data management system (http://www.tcmcec.net/) will be used to collect and manage data. Quality control will be implemented according to good clinical practice.

DISCUSSION:

Previous TCM clinical trials have investigated if adding GLDS to standard routine treatment can improve the therapeutic effect in patients with unstable angina pectoris. This study focuses on the safety and efficacy of GLDS on unstable angina pectoris of phlegm-blood stasis type, in order to obtain relevant clinical evidence.

TRIAL REGISTRATION:

This study is approved by the Ethics Committee of Guang'anmen Hospital of the China Academy of Chinese Medical Sciences (no. 2019-187-KY-02) and is registered with chictr.org (registration number ChiCTR2000031780).

• Authors: Jianbo Guo, Shuang Dai, Yukun Ding, Haoqiang He, Hui Zhang, Wenchao Dan, Kun Qin, Hui Wang, Anqi Li, Peipei Meng, Shangjin Li, Qingyong He
• Journal: Medicine (Medicine (Baltimore)) Vol. 99 Issue 33 Pg. e21593 (Aug 14 2020) ISSN: 1536-5964 [Electronic] United States
• PMID: 32872012 (Publication Type: Clinical Trial Protocol, Journal Article)

Chemical References

• dan-shen root extract
• Drugs, Chinese Herbal

Topics

• Adult
• Aged
• Female
• Humans
• Male
• Middle Aged
• Angina, Unstable (drug therapy, therapy)
• Double-Blind Method
• Drugs, Chinese Herbal (administration & dosage, adverse effects, therapeutic use)
• Medicine, Chinese Traditional (methods)
• Salvia miltiorrhiza
• Feasibility Studies
• Randomized Controlled Trials as Topic